1Raise LG,Prestwood KM.Estrogen and the risk of fracture:new data,new questions[J].New EngJ Med,1998,339(11):767.
2Rossouw JE,Anderson GL,Prentice RL,et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the women's health initiative randomized controlled trial [J].JAMA,2002,288(3):321.
3Chen CL,Weiss NS,Newcomb P,et al.Hormone replacement therapy in relation to breast cancer [J].JAMA,2002,287 (6):734.
4Hodis HN,Mack WJ,Azen SP,et al.Hormone therapy and the progression of coronary - artery atherosclerosis in postmenopausal women[J].N Engl J Med,2003,349(6) :535.
5Beral V,Million Women Study Collaborators.Breast cancer and hormone- replacement therapy in the Million Women Study [J].Lancet,2003,362(9382):419.
6Khan MA,Herzog CA,Peter JV St,et al.The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite - suppressant drugs [J].N Engl J Med ,1998,339(11) :713.
7Hirsch J.Magic bullet for obesity.BMJ,1998,317 (7166):1136.
4Wright JM. The double-edged sword of COX-2 selective NSAID [J] . CMAJ, 2002, 167(10):1131.
5Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associatad with the use of celecoxib and rofecoxib [J] .Drug Safety, 2002, 25(7):537.
6Juni P, Dieppe P. Older people should not be prescribed' Coxibs' in place of conventional NSAIDs [J] . Age Aging, 2004, 33(2):100.
7Juni P, Rutjes AWS, Dieppe PA. Are selective COX-2inhibitors superior to traditional non-steroid anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case [J] . BMJ, 2002,324:1287.
8Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors [J] . JAMA, 2001, 286(8); 954.
9Crofford E J, Oates JC, McCune WJ, et al. Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors [J] . Arthritis rheum, 2000, 43(8):1891.
10Steinbach G, lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis [J] . N Engl J Med, 2000,342(260): 1946.
